US approves treatment that alters patients’ cells to attack childhood leukemia – Minneapolis Star Tribune
Minneapolis Star Tribune |
US approves treatment that alters patients’ cells to attack childhood leukemia
Minneapolis Star Tribune The CAR–T cell treatment developed by Novartis and the University of Pennsylvania is the first type of gene therapy to hit the U.S. market — and one in a powerful but expensive wave of custom-made “living drugs” being tested against blood cancers and … |
Minneapolis Star Tribune |
US approves treatment that alters patients’ cells to attack childhood leukemia
Minneapolis Star Tribune The CAR–T cell treatment developed by Novartis and the University of Pennsylvania is the first type of gene therapy to hit the U.S. market — and one in a powerful but expensive wave of custom-made “living drugs” being tested against blood cancers and … |
|
CSL Behring pays $91M upfront for early stage gene therapy
BioPharma Dive CSL Behring has bought out Calimmune, a Tucson-based stem cell gene therapy biotech, for a $91 million upfront payment. The deal gives CSL Behring access to Calimmune’s stem cell platforms Select+ and Cytegrity, as well as its CAL-H product candidate, … |
|
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Business Wire (press release) The FDA granted Priority Review and Orphan Drug Designation to Actemra for the treatment of CAR T cell-induced CRS based on the rare, severe and life-threatening nature of CRS and available data on the safety and efficacy of Actemra. Priority Review … |
Business Insider |
Novartis AG’s CAR–T cell therapy for leukemia approved by FDA in ‘historic action’; price to be based on outcomes
MarketWatch Novartis AG’s NVS, -1.01% CAR–T cell therapy was approved by the Food and Drug Administration on Wednesday, making it the first gene therapy to be available in the U.S. Novartis’ Kymriah was approved for young people up to age 25 with a form of acute … Novartis receives first ever FDA approval for a CAR–T cell therapy, Kymriah(TM) (CTL019), for children and young …GlobeNewswire (press release) FDA approval brings first gene therapy to the United StatesFDA.gov A cancer treatment that one expert called the ‘most exciting thing I’ve seen in my lifetime’ just got approvedBusiness Insider Chicago Tribune –OncLive all 25 news articles » |
|
What’s Next for Gene Therapy to Treat Cancer
WebMD (blog) The FDA’s approval of a treatment that uses genetically modified immune cells to fight a type of childhood leukemia has opened the door to a new way of fighting cancer. The treatment, known as CAR-T cell therapy, is approved for children with acute … |
|
Novartis gene therapy for leukemia wins US approval
Reuters UK Aug 30 (Reuters) – The U.S. Food and Drug Administration (FDA) on Wednesday approved Novartis AG’s keenly anticipated leukemia treatment, marking the first gene therapy approval in the United States. The drug, Kymriah, was approved for patients up to … |
|
I Was Planning My Funeral. This Therapy Was My Last Chance.
WebMD (blog) An infusion of cells can cause the sudden release of chemicals that signal the body to produce inflammation—this cytokine release syndrome sends one-third to one-half of patients who get CAR–T into intensive care. It can also cause neurologic side … |